Clive S. Zent, M.D.

Clive S. Zent, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester, NY 14642

Administrative: (585) 273-3258
Fax: (585) 273-1042

Professional Bio

Dr. Clive Zent is a highly experienced hematologist and internationally recognized researcher and expert in the care of patients with chronic lymphocytic leukemia (CLL) and related lymphoid malignancies. While training in Hematology at the University of Chicago, Dr. Zent studied the molecular genetics of hematological malignancies in the laboratory of Dr. Janet Rowley. His clinical and research interest in CLL started as an attending physician at the Central Arkansas Veterans Healthcare System and continued when he joined the staff of the Mayo Clinic in Rochester MN in 2003. In 2013 he was appointed to the faculty of the Wilmot Cancer Center at the University of Rochester Medical Center as Professor of Medicine and director of the Chronic Lymphocytic Leukemia program.



Dr. Zent's research has improved our understanding of the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complicating CLL. His goal as a clinician, researcher and teacher is to continue to improve treatment and outcome for patients with CLL.

Research Bio

Dr. Clive Zent is a highly experienced hematologist and internationally recognized researcher and expert in the care of patients with chronic lymphocytic leukemia (CLL) and related lymphoid malignancies. While training in Hematology at the University of Chicago, Dr. Zent studied the molecular genetics of hematological malignancies in the laboratory of Dr. Janet Rowley. His clinical and research interest in CLL started as an attending physician at the Central Arkansas Veterans Healthcare System and continued when he joined the staff of the Mayo Clinic in Rochester MN in 2003. In 2013 he was appointed to the faculty of the Wilmot Cancer Center at the University of Rochester Medical Center as Professor of Medicine and director of the Chronic Lymphocytic Leukemia program.



Dr. Zent's research has improved our understanding of the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complicating CLL. His goal as a clinician, researcher and teacher is to continue to improve treatment and outcome for patients with CLL.

Awards & Honors (Local)

Teacher of the Year in Hematology | Mayo Fellows Association, College of Medicine | Mayo Clinic 2008
Kaminer Fellowship (Travel Award) | University of Chicago | Chicago, IL 1995
Degree with Distinction | University of the Witwatersrand | South Africa 1983

Recent Journal Articles

Showing the 5 most recent journal articles. 132 available »

2016 Jul 29
Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP. "Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions." The Journal of immunology : official journal of the American Association of Immunologists. 2016 Jul 29; Epub 2016 Jul 29.
2016 Jul 8
Williams AM, Zent CS, Janelsins MC. "What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research." British journal of haematology. 2016 Jul 8; Epub 2016 Jul 08.
2016 Jul
Zent CS, Bowen DA, Conte MJ, LaPlant BR, Call TG. "Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study." Leukemia & lymphoma. 2016 Jul; 57(7):1585-91. Epub 2015 Dec 24.
2016 May
Zent CS. "Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation." Leukemia & lymphoma. 2016 May; 57(5):985-6. Epub 2016 Jan 04.
2016 Mar
Zent CS, Wang XV, Ketterling RP, Hanson CA, Libby EN, Barrientos JC, Call TG, Chang JE, Liu JJ, Calvo AR, Lazarus HM, Rowe JM, Luger SM, Litzow MR, Tallman MS. "A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)." American journal of hematology. 2016 Mar; 91(3):308-12. Epub 2016 Feb 09.

Current Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD) - Primary
Professor - Cancer Center

Specialties

Hematology - American Board of Internal Medicine
Internal Medicine - American Board of Internal Medicine

Education

MBBCh | University of the Witwatersrand1983
MMed | Internal Medicine | University of Cape TownAttended 1987 - 1991

Post-Doctoral Training & Residency

Residency in Internal Medicine at University of Arkansas College of Medicine07/01/1996 - 6/30/1997
Fellowship in Hematology at University of Chicago Medical Center07/01/1993 - 6/30/1996
Residency in Internal Medicine at Groote Schuur Hospital - University of Cape Town02/01/1987 - 1/31/1991
Internship in Internal Medicine at University of Witwatersrand01/01/1984 - 12/31/1984